You have 9 free searches left this month | for more free features.

CD25 Positive

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Hairy Cell Leukemia Trial run by the NCI (Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin)

Active, not recruiting
  • Hairy Cell Leukemia
  • Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Apr 13, 2022

CD19+ Relapse/Refractory B-ALL Trial in Beijing (CAR-T-19 Cells)

Recruiting
  • CD19+ Relapse/Refractory B-ALL
  • CAR-T-19 Cells
  • Beijing, Beijing, China
    Chinese PLA General Hospital
Feb 26, 2022

The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25

Not yet recruiting
  • The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
  • CD25 prophylaxis
  • (no location specified)
Jun 20, 2023

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Tregs CD25 CXCL9 in Vitiligo

Not yet recruiting
  • Vitiligo
  • +3 more
  • ELIZA , Flowcytometry
  • (no location specified)
Oct 3, 2022

Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Lymphoma
  • CD70-targeting CAR-T cells
  • Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 9, 2023

CD70-positive Advanced Urologic Tumors Trial in Shanghai (Anti-CD70 CAR-T cells)

Recruiting
  • CD70-positive Advanced Urologic Neoplasms
  • Anti-CD70 CAR-T cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Aug 11, 2023

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in United States (ADCT-301)

Terminated
  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Atlanta, Georgia
  • +10 more
Feb 12, 2020

CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

Terminated
  • CD20-positive Non-Hodgkin Lymphoma
  • Rituximab + MG4101
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 24, 2022

T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia Trial in Beijing, Shenzhen,

Recruiting
  • T-cell Acute Lymphoblastic Leukemia
  • +3 more
  • Universal CD7-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 17, 2023

Solid Tumor, Adult Trial in Beijing (CD70-targeting CAR-T cells)

Recruiting
  • Solid Tumor, Adult
  • CD70-targeting CAR-T cells
  • Beijing, Iotherapeutic Department Of Chinsese PLA Gereral Hospital, China
    China
Jul 8, 2023

Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer Trial in Nanchang (CD70 CAR-T cells)

Recruiting
  • Renal Cell Carcinoma
  • +4 more
  • CD70 CAR-T cells
  • Nanchang, Jiangxi, China
    The First Affiliated Hospital of Nanchang University
Aug 23, 2023

Health Status of Children Born After Assisted Reproductive

Recruiting
  • Children Born After Assisted Reproductive Technologies
  • +2 more
  • hemogram examination
  • Almaty, Kazakhstan
    Sevara ilmuratova
Oct 17, 2023

CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

Recruiting
  • CD20-positive Non-Hodgkin Lymphoma
  • EX103 injection
  • Zhengzhou, Henan, China
  • +3 more
Aug 28, 2023

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Tumors, Hematologic Tumors, Tumors by Site Trial in Hangzhou (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +3 more
  • RD13-02 cell infusion
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Feb 6, 2023

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023

Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory

Active, not recruiting
  • Peripheral T Cell Lymphoma
  • Pediatric Hodgkin Lymphoma
  • Brentuximab Vedotin (Genetical Recombination)
  • Tokyo, Japan
    Takeda Selected Site
Oct 11, 2022

Acute Myeloid Leukemia Trial in Valencia (AFM28)

Recruiting
  • Acute Myeloid Leukemia
  • Valencia, Spain
    Hospital Universitari i Politècnic La Fe
Apr 5, 2023

Leukemia, Myeloid, Chronic, AML, Leukemia, Lymphocytic, Acute Trial in Minneapolis (biological, drug, radiation)

Terminated
  • Leukemia, Myeloid, Chronic
  • +8 more
  • Stem Cell Transplant
  • +5 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Dec 31, 2020

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, biological, drug,

Recruiting
  • Acute Lymphoblastic Leukemia
  • +3 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Jan 12, 2023